Saygin, C., Hirsch, C., Przychodzen, B., Sekeres, M. A., Hamilton, B. K., Kalaycio, M., . . . Advani, A. S. (2018). Mutations in DNMT3A, U2AF1, and EZH2 identify intermediate-risk acute myeloid leukemia patients with poor outcome after CR1. Blood Cancer J.
Citación estilo ChicagoSaygin, Caner, et al. "Mutations in DNMT3A, U2AF1, and EZH2 Identify Intermediate-risk Acute Myeloid Leukemia Patients With Poor Outcome After CR1." Blood Cancer J 2018.
Cita MLASaygin, Caner, et al. "Mutations in DNMT3A, U2AF1, and EZH2 Identify Intermediate-risk Acute Myeloid Leukemia Patients With Poor Outcome After CR1." Blood Cancer J 2018.
Nota: a formatação da citação pode não corresponder 100% ao definido pela respectiva norma.